Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... But Novo said Wednesday it expects slower growth in 2025 compared to the prior year. The 2024 outlook estimated growth between ...

Novo Nordisk forecast slower sales growth for 2025 of between 16% to 24 ... work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...